Equillium, Inc. · NASDAQ:EQ

Equillium — Investor Presentation (August 2025)

43 slides from Equillium's investor presentation, August 2025

  1. Slide 1: EQ504: Targeting AhR to Promote Mucosal Healing in Gastro-intestinal Disease

    EQ504: Targeting AhR to Promote Mucosal Healing In Gastro-intestinal Disease August 2025

  2. Slide 2: Forward-Looking Statements and Other Disclaimers

    Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements about Equillium, Inc. (the “Company”). In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “

  3. Slide 3: Advancing Novel High-Impact A&I Therapeutics

    Advancing Novel High-Impact A&I Therapeutics Leveraging deep understanding of immunobiology and its role in disease to pioneer new products for severe autoimmune and inflammatory disorders with high unmet medical need Development Pipeline Indication Pre-Clinical IND Enabling Phase 1 Phase 2 Phase 3

  4. Slide 4: Equillium Overview

    Equillium Overview EQ504 – Oral Aryl Hydrocarbon Modulator • The aryl hydrocarbon receptor (AhR) is critical to barrier organ physiology and immunology • Modulating AhR is validated in the treatment of both inflammatory skin & GI disease through VTAMA®️ & indigo naturalis • EQ504 is a potent, select

  5. Slide 5: Targeting The Aryl Hydrocarbon Receptor in Barrier Tissue Inflammation

    Targeting The Aryl Hydrocarbon Receptor in Barrier Tissue Inflammation

  6. Slide 6: The Aryl Hydrocarbon Receptor (AhR): Activating the AhR Pathway

    The Aryl Hydrocarbon Receptor (AhR) Activating the AhR Pathway AhR Ligands 1 2 Signaling begins when a The AhR ligand complex 1 Cytoplasm ligand binds to AhR in the translocates to the nucleus cell cytoplasm, forming an and heterodimerizes with the AhR AhR ligand complex AhR nuclear translocator (AR

  7. Slide 7: AhR in Barrier Tissue Physiology and Immunology

    AhR in Barrier Tissue Physiology and Immunology Maintaining barrier function AhR expression is high in barrier tissues and Immune cell regulation mucosal epithelia such as skin, lung, gut, and eye Anti-inflammatory effects Tissue repair and regeneration Esser & Rannug., Pharmacol Rev., 2015; Rothham

  8. Slide 8: Challenges in the Development of AhR targeted Therapeutics

    Challenges in the Development of AhR targeted Therapeutics Despite a paradigm shift in our understanding of AhR in disease physiology, there are still development challenges to generate AhR modulators for therapeutic use While AhR binds a diverse array of ligands there have been two key challenges i

  9. Slide 9: Tapinarof Validates AhR as a Therapeutic Target

    Tapinarof Validates AhR as a Therapeutic Target Silverberg et al. J Allergy Clin Immunol., 2024 9 Abbreviations: AhR, aryl hydrocarbon receptor

  10. Slide 10: Biologic-like Efficacy from a Small Molecule

    Biologic-like Efficacy from a Small Molecule Tapinarof activates AhR pathways and exhibits biologic-like efficacy – the first novel, non-steroidal, topical agent launched for psoriasis in the U.S. in more than 25 years Baseline 4 weeks 12 weeks Up to 48% of adult patients achieved PASI75 vs ~10% of

  11. Slide 11: Modulation of AhR for the Treatment of Ulcerative Colitis & EQ504

    Modulation of AhR for the Treatment of Ulcerative Colitis & EQ504

  12. Slide 12: Mucosal Healing in Ulcerative Colitis: An Unfulfilled Promise

    Mucosal Healing in Ulcerative Colitis: An Unfulfilled Promise • >15 approved immunomodulatory drugs, yet therapeutic efficacy remains low • Clinical remission rates up to ~30% Inflammatory condition • Systemic suppression of immune system = significant potential side effects affecting ~5 million • P

  13. Slide 13: AhR Pathway is Key to Maintaining Gut Health

    AhR Pathway is Key to Maintaining Gut Health AhR activated pathways are critical for maintaining intestinal homeostasis and can protect against inflammatory bowel disease by regulating barrier function & immune responses Barrier function & Immune Cell Anti-inflammatory Tissue Repair Regulation Cytok

  14. Slide 14: Tryptophan Metabolites Modulate Gut Homeostasis via AhR

    Tryptophan Metabolites Modulate Gut Homeostasis via AhR Tryptophan metabolites are well characterized in their maintenance of gut homeostasis and are protective against colitis in animal models but have limitations as therapeutics Host Metabolism Synthesized in situ in tissues Diverse array of AhR m

  15. Slide 15: Indirubin/Indigo: Exogenous AhR Modulators

    Indirubin/Indigo: Exogenous AhR Modulators Indirubin and Indigo are naturally-occurring, exogenous, AhR modulators found in plants (indigo naturalis) that modulate barrier physiology and immunology Indirubin Indigo • Derived from plant biosynthesis of tryptophan EC50 EC50 and validated as the active

  16. Slide 16: Modulation of AhR Leads to High Rates of Clinical Remission

    Modulation of AhR Leads to High Rates of Clinical Remission Studies of ulcerative colitis patients treated with indigo naturalis demonstrate on-target engagement of AhR through increased intestinal CYP1A1 and high levels of clinical remission Indigo Naturalis (Qing-Dai) A traditional botanical medic

  17. Slide 17: ITE: An Endogenous, Non-toxic AhR Modulator

    ITE: An Endogenous, Non-toxic AhR Modulator ITE is a naturally-occurring, endogenous, non-toxic AhR modulator found in the gut and lungs where it is synthesized in situ to modulate barrier physiology and immunology ITE EC50 • Discovered in 2002, synthesized in situ in gut ~ 150 nM and lung tissues f

  18. Slide 18: ITE: Tailor-made Scaffold for Therapeutic Development

    ITE: Tailor-made Scaffold for Therapeutic Development A deep understanding of AhR, ITE biology and structure activity relationships (SAR) led to a successful medicinal chemistry campaign to identify an optimized therapeutic ITE bound to PAS-B domain pocket in AhR Unoccupied hydrophobic pocket • Exte

  19. Slide 19: EQ504 is a Potent Analog of ITE with Drug-like Properties

    EQ504 is a Potent Analog of ITE with Drug-like Properties Derived from ITE, EQ504 is a potent modulator of AhR and downstream pathways that demonstrates strong in vitro / vivo activity in models of inflammation and barrier repair • EQ504 highly potent and selective modulator of Induction of CYP1A1 i

  20. Slide 20: Colonic Delivery of EQ504 Reduces Systemic Exposure

    Colonic Delivery of EQ504 Reduces Systemic Exposure In vivo experiments demonstrate localized delivery of EQ504 directly to the colon of rats, results in 25x greater exposures in colon tissues versus blood Routes of Fold Increase of Peak (6hr) Administration Colonic/Systemic Exposure Oral >25x Colon

  21. Slide 21: Targeting the Colon to Treat Ulcerative Colitis

    Targeting the Colon to Treat Ulcerative Colitis Targeting the colon in UC patients is a clinically validated approach affording EQ504 a differentiated product profile and several potential therapeutic benefits • Clinically and commercially validated enteric coating system available to target the col

  22. Slide 22: Potential to Create Value in Phase 1 Proof of Mechanism Study

    Potential to Create Value in Phase 1 Proof of Mechanism Study Efficacy of indigo naturalis in UC patients established; clinical data demonstrating a favorable safety profile & proof of mechanism for EQ504 has potential to create value • Multiple clinical studies of indigo naturalis establish strong

  23. Slide 23: Positioning & Market Opportunity

    Positioning & Market Opportunity

  24. Slide 24: Opportunity for Broad Therapeutic Positioning

    Opportunity for Broad Therapeutic Positioning EQ504 positioned to have significant utility across multiple lines of therapy Disease Severity 1 2 Steroids → Oral, Pre- Biologic Cyclosporine Surgical 5-ASAs Biologics Thiopurines Biologics Failures / Tacrolimus Intervention 3 1 Pre-biologic: Substantia

  25. Slide 25: Large Market Opportunity and Active M&A

    Large Market Opportunity and Active M&A Ulcerative colitis market expected to exceed $12B in annual worldwide sales by 2030, availability of safe and effective oral agents expected to expand the pool of treated patients Approximately ~900,000 patients in US & ~600,000 Acquired by Acquired by License

  26. Slide 26: Corporate

    a GQuilliun ——— Corporate

  27. Slide 27: Accomplished Executive Leadership

    Accomplished Executive Leadership Bruce Steel, CFA Steve Connelly, PHD Christine Zedelmayer CHIEF EXECUTIVE OFFICER CHIEF SCIENTIFIC OFFICER CHIEF OPERATING OFFICER BioMed Ventures • Rincon BioMed Ventures • aTyr Pharma Amylin • Amgen • Ligand Anaphore • Ambit The Scripps Research Institute Joel Rot

  28. Slide 28: Equillium Intellectual Property

    Equillium Intellectual Property AhR Portfolio Aryl Hydrocarbon Receptor Modulators - Compositions/Methods 3 patent families 8 issued patents 5 applications pending AhR Compounds - Compositions/Methods Current EQ Filings Future EQ Filings Chiral AhR Compounds - Compositions/Methods EQ504 - Compositio

  29. Slide 29: Scientific Advisors

    Scientific Advisors Professor Francisco J. Quintana, PhD Dr. Thomas Daniel, MD Harvard University & Associate Member, Broad Institute. Venture Partner, Entrepreneur & Industry Veteran Dr. Quintana is immunologist focused on investigating signaling pathways Over 20 years of experience leading and bui

  30. Slide 30: Clinical Advisors

    Clinical Advisors Professor Bruce Sands Brian Feagan Feinstein IBD Clinical Center, Mt Sinai Hospital Venture Partner, Entrepreneur & Industry Veteran Dr. Sands is an expert in the management of inflammatory bowel diseases Dr. Brian Feagan is a gastroenterologist, his research focus is the design, a

  31. Slide 31: Thank you

    Thank you www.equilliumbio.com

  32. Slide 32: Pre-clinical Data

    a GQuilliun ——— Pre-clinical Data

  33. Slide 33: Modulation of AhR Modulates Tissue and Immune Cell Biology

    Modulation of AhR Modulates Tissue and Immune Cell Biology EQ504 impacts multiple cells in the gut 11. Drives M2 polarization which leads to an increase in IL-22 production. 22. Induces CD39 and TIGIT expression of Tregs which also leads to IL-10 and IL-22 cytokine release. 33. Decreases pathogenic

  34. Slide 34: EQ504 Protects Ex Vivo Intestinal Barrier Function from Inflammation

    EQ504 Protects Ex Vivo Intestinal Barrier Function from Inflammation Activation of AhR pathways by EQ504 protects gut epithelial barrier function which is disrupted by pro-inflammatory cytokines during stress, damage or disease Modulation of gut epithelial barrier function ex vivo 150 Barrier Functi

  35. Slide 35: EQ504 Promotes Ex Vivo Intestinal Epithelial Wound Healing

    EQ504 Promotes Ex Vivo Intestinal Epithelial Wound Healing EQ504 activates AhR and induces CYP1A1 and other downstream pathways such as IL-22 which leads to increased levels of wound healing in epithelial cells Vehicle EQ504 10nM Indirubin 50nM ✱ CYP1A1 mRNA (fold change) 125 Vehicle 80 2.0 ✱✱ ✱ IL2

  36. Slide 36: EQ504 Modulates Key Immune Cells In Vitro

    EQ504 Modulates Key Immune Cells In Vitro Modulation of AhR by EQ504 increases the number and function of suppressive Treg cells that inhibit activity of Th1 and Th17 cells while also reducing the number of pathogenic Th17 cells Suppressive Treg Cells Pathogenic Th17 Cells Treg ✱✱✱ ✱✱✱✱ 80 25 ✱✱✱ Ve

  37. Slide 37: EQ504 Reduces Frequency of CD86+ M1 Macrophages

    EQ504 Reduces Frequency of CD86+ M1 Macrophages Donor 0759 Donor 7070 • CD86 is a co-stimulatory molecule expressed on antigen presenting cells (APCs) and plays a crucial role in T cell 100 100 activation and survival % CD86+ M1 cells % CD86+ M1 cells 80 80 • CD86 is also highly expressed on M1 macr

  38. Slide 38: EQ504 Upregulates IRF4 Expression on M2 Macrophages

    EQ504 Upregulates IRF4 Expression on M2 Macrophages EQ504 upregulates interferon regulatory factor 4 (IRF4), a key regulator of M2 macrophage activation and polarization that contributes to tissue repair and resolution of inflammation M2 IRF4 ✱ ✱ 2.0 normalized to vehicle IRF4 expression 1.5 1.0 0.5

  39. Slide 39: EQ504 Reduces Production of M1-associated Cytokines

    EQ504 Reduces Production of M1-associated Cytokines EQ504 modulates activity of M1 macrophages leading to reduction of key inflammatory cytokines important in the development and progression of ulcerative colitis IL-1β TNFα ✱✱ 15000 150 ✱✱ 10000 100 pg/mL pg/mL 5000 50 Cytokine data 0 0 Vehicle 1 10

  40. Slide 40: EQ504 Demonstrates Dose-Dependent Activity in DSS Colitis Model

    EQ504 Demonstrates Dose-Dependent Activity in DSS Colitis Model DSS Colitis Animal Model EQ504 Demonstrates Dose • Dextran Sodium Sulfate Response in DSS colitis Model DSS (7days) (DSS) induced colitis is the most widely used in vivo DSS Body Weight Change Body Weight Change by Day 10 (%) model of I

  41. Slide 41: EQ504 Demonstrates Activity in Treating Experimental Colitis

    EQ504 Demonstrates Activity in Treating Experimental Colitis DSS Colitis Animal Model EQ504 is efficacious at • Dextran Sodium Sulfate 1 mg/kg in DSS colitis DSS (7days) (DSS) induced colitis is the most widely used in vivo model of IBD Colon epithelial • Cyclosporin (CSA), a broad breakdown and str

  42. Slide 42: EQ504 Induces Anti-Inflammatory Cytokines in Colon Tissues

    EQ504 Induces Anti-Inflammatory Cytokines in Colon Tissues AhR modulators EQ504 and indirubin activate AhR pathways as demonstrated by increased CYP1A1 and anti-inflammatory cytokine expression in DSS colitis colons CYP1A1 expression IL-22 expression IL-10 expression demonstrates target engagement *

  43. Slide 43: EQ504 is Protective in DSS Colitis by Histology

    EQ504 is Protective in DSS Colitis by Histology Vehicle EQ504 1mg/kg CSA 75mg/kg Loss of crypt Preserved structure morphology Hypertrophy Edema Lymphoid Reduced aggregate lymphoid aggregate Immune infiltration Reduced infiltration Mucosal erosion Preserved mucosa 43 Sections taken from distal colon

Equillium — Investor Presentation (August 2025) on 6ix